Sorafenib, an oral multi-kinase inhibitor, and Avastin, an anti-VEGF monoclonal antibody, are two anti-angiogenic agents currently approved for treating unresectable or metastatic HCC (Morse et al., 2019). Here, VEGFA is linked to hepatocellular carcinoma.